Difference between revisions of "Quinupristin/dalfopristin"
(Text replacement - "5 mg" to "5mg")
(Text replacement - "pruritis" to "pruritus")
|Line 37:||Line 37:|
Revision as of 17:16, 27 October 2016
- Treatment of vancomycin-resistant Enterococcus faecium, as well as nosocomial pneumonias and infections secondary to IV catheters (1)
- Dosage Forms: 500mg vials, diluted into 250 mL and given over 60 mins
- Routes of Administration: IV
- Common Trade Names: Synercid
- VRE: 7.5mg/kg IV q8 hrs for minimum 7 days
- skin infections: 7.5mg/kg IV q12 hrs for minimum 7 days
- safety and efficacy has not been studied in children
- Pregnancy Rating: B
- Lactation risk: unknown whether secreted in human breast milk. Caution should be exercised when administering to nursing mothers. (2)
- no adjustments for renal impairment
- dosage may need to be adjusted in patients with cirrhosis, however specific dose modification is not known at this time (2)
- Allergy to class/drug
- pain and inflammation at infusion site
- Half-life: Quinupristin: 3 hrs; Dalfopristin: 1 hr
- Metabolism: significantly interacts with the CYP 3A4 system.
- 1. JP Manzanella. "Quinupristin-Dalfopristin: A New Antibiotic for Severe Gram-Positive Infections." American Family Physician. 2001 Dec 1;64(11):1863-1867.
- 2. U.S. Food and Drug Administration. Synercid I.V. November 2007. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050748s008,050747s008lbl.pdf